Zobrazeno 1 - 10
of 12 138
pro vyhledávání: ''
Autor:
Ulrich Gatzemeier, Michael Boyer, Paolo Paoletti, Salih Emri, Christian Manegold, Claude Denham, Nicholas J. Vogelzang, James J. Rusthoven, James T. Symanowski, Clet Niyikiza, E. Kaukel, Pierre Ruffié
Publikováno v:
Journal of Clinical Oncology. 41:2125-2133
PURPOSE Patients with malignant pleural mesothelioma, a rapidly progressing malignancy with a median survival time of 6 to 9 months, have previously responded poorly to chemotherapy. We conducted a phase III trial to determine whether treatment with
Autor:
Lajos Pusztai, Gabriel N. Hortobagyi, Bryan T. Hennessy, Massimo Cristofanilli, Chafika Mazouni, Fabrice Andre, Attila Tordai, W. Fraser Symmans, Cornelia Liedtke, Marjorie C. Green, Ana M. Gonzalez-Angulo, Kenneth R. Hess, Jaime A. Mejia
Publikováno v:
Journal of Clinical Oncology. 41:1809-1815
PURPOSE Triple-negative breast cancer (TNBC) is defined by the lack of estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER-2) expression. In this study, we compared response to neoadjuvant chemotherap
A Systematic Comparison of Overall Survival Between Men and Women With Triple Negative Breast Cancer
Autor:
Mohammad Muhsin Chisti, Swechchha Silwal, Geetha Krishnamoorthy, Siddhartha Yadav, Sumeet Kumar Yadav
Publikováno v:
Clinical Breast Cancer. 22:161-169
Introduction Triple-negative breast cancer (TNBC) in men is very rare. The clinical characteristics, prognostic factors, and overall survival of men with TNBC have not been characterized. Methods The study population consisted of men and women with a
Autor:
Ashley J. Schlafstein, Karen D. Godette, Shannon Kahn, Mylin A. Torres, Subir Goyal, Jolinta Lin, Trevor J. Royce, Sagar A. Patel, Yuan Liu
Publikováno v:
Clinical Breast Cancer. 22:127-135
Neoadjuvant chemotherapy (NAC) is increasingly used for operable breast cancer (BC). Appropriate radiation therapy (RT) fields (ie, whole breast [WB] ± regional nodal irradiation [RNI]) in patients who were clinically node positive (cN1) but convert
Autor:
Jitsuo Usuda, Susumu Takeuchi, Kengo Nagashima, Noriko Motoi, Masahiro Seike, Jun Matsubayashi, Hideaki Shiraishi, Kazufumi Honda, Shun-ichi Watanabe, Rintaro Noro, Kaoru Kubota, Xue Meng, Tatsuya Inoue, Huang Wilber, Ayumi Kashiro, Tetsuya Okano, Yukihiro Yoshida, Shinobu Kunugi, Akihiko Gemma, Norihiko Ikeda
Publikováno v:
Cancer Science. 113:1002-1009
Although adjuvant tegafur/uracil (UFT) is recommended for patients with completely resected stage I non-small cell lung cancer (NSCLC) in Japan, only one-third of cases has received adjuvant chemotherapy according to real-world data. Therefore, robus
Autor:
Ariadna Juarez-Garcia, John C O'Donnell, John R. Penrod, Mats Rosenlund, Simon Ekman, Jens Benn Sørensen, Anne Mette Kejs, Pia Horvat, L. Lacoin, Odd Terje Brustugun, Dony Patel, M. Daumont
Publikováno v:
Sørensen, J B, Horvat, P, Rosenlund, M, Kejs, A M, Patel, D, Juarez-Garcia, A, Lacoin, L, Daumont, M J, Penrod, J R, O'donnell, J C, Brustugun, O T & Ekman, S 2022, ' Initial treatment and survival in Danish patients diagnosed with non-small-cell lung cancer (2005-2015) : SCAN-LEAF study ', Future Oncology, vol. 18, no. 2, pp. 205-214 . https://doi.org/10.2217/fon-2021-0746
Aim: To describe initial treatment patterns and survival of patients diagnosed with non-small-cell lung cancer (NSCLC) in Denmark, before immune checkpoint inhibitor and later-generation tyrosine kinase inhibitor use. Patients & methods: Adults diagn
Publikováno v:
Cancer Medicine, Vol 11, Iss 2, Pp 392-405 (2022)
Cancer Medicine
Cancer Medicine
Background Anal squamous cell carcinoma (ASCC) is the main subtype of anal cancer and has great heterogeneity in prognosis. We aimed to construct a nomogram for predicting their 1‐, 3‐, and 5‐year overall survival (OS) rates. Methods Patients w
Autor:
Marloes A. G. Elferink, Manon C.W. Spaander, Esther Toes-Zoutendijk, Evelien Dekker, Iris D. Nagtegaal, Geraldine R. Vink, Monique E. van Leerdam, Iris Lansdorp-Vogelaar, Sabine Siesling
Publikováno v:
European Journal of Cancer, 161, 38-43
European Journal of Cancer, 161, pp. 38-43
European Journal of Cancer, 161, 38-43. ELSEVIER SCI LTD
European journal of cancer, 161, 38-43. Elsevier
European Journal of Cancer, 161, 38-43. Elsevier Limited
European Journal of Cancer, 161, 38-43. Elsevier Ltd.
European Journal of Cancer, 161, pp. 38-43
European Journal of Cancer, 161, 38-43. ELSEVIER SCI LTD
European journal of cancer, 161, 38-43. Elsevier
European Journal of Cancer, 161, 38-43. Elsevier Limited
European Journal of Cancer, 161, 38-43. Elsevier Ltd.
Many countries had to suspend their colorectal cancer (CRC) screening pro-gramme as a result of the COVID-19 pandemic. This eventually may lead to postponed diag-noses of premalignant lesions and CRC, resulting in increased incidence or more advanced
Publikováno v:
International Journal of Radiation Oncology*Biology*Physics. 112:40-51
The omission of radiation therapy (RT) in older women with stage 1 estrogen-receptor-positive (ER+) breast cancer receiving endocrine therapy (ET) is an acceptable strategy based on randomized trial data. Less is known about the omission of ET with o
Autor:
Isabelle Ghelerter, Marie-Hélène Lafeuille, Mike Durkin, Joyce LaMori, Patrick Lefebvre, Lorie Ellis, Carmine Rossi, Dominic Pilon, Xuehua Ke
Publikováno v:
Future Oncology. 18:231-243
Aims: In light of the extended overall survival and improved quality of life provided by advanced prostate cancer (PC) oral therapies, this study aimed to describe treatment adherence to advanced PC oral therapies and evaluate associated patient char